Efficient Hit-to-Lead Finding Capabilities for Potent and Selective Biological Outcomes

Efficient Hit-to-Lead Finding Capabilities for Potent and Selective Biological Outcomes
Version:
21301

Year:
2022

 

Overview: Key Tools for Designing Successful Fully Tailored Screening

 

Identifying biologically and pharmacologically active compound series with desired potency, selectivity, and ADME-toxicology properties in early phases of drug discovery requires team expertise across multiple disciplines, including chemistry, high-throughput screening (HTS), ADME, safety pharmacology, toxicology, bioinformatics, automation and translational biology.